Enhanced Genomics extends Series A funding to USD $19 million to drive development of therapeutics pipeline
Apărare
Enhanced Genomics Sep 17 2025 Enhanced Genomics ('Enhanced'), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced it has completed a financing round, extending its total Series A funding to $19 million. Investors in this latest funding are BGF, Parkwalk and Meltwind. The funding will be used to expand Enhanced's internal therapeutic pipeline in common diseases, including autoimmune
astăzi